

CURRICULUM VITAE

NAME: Ganesh A. Thakur, Ph.D.

OFFICE ADDRESS: Department of Pharmaceutical Sciences, 140 The Fenway, Room # 145,
Northeastern University, Boston, MA 02115
Telephone: 617-373-8163 (Office),

860-983-1021 (cell)
Fax: 617-373-8886;
E-Mail: g.thakur@northeastern.edu

CITIZENSHIP: U.S. Citizen

I. EDUCATION AND EMPLOYMENT HISTORY:

1. EDUCATION

<u>Year</u>	<u>Degree</u>	<u>Institution</u>
1990-1993	B.S. (Chemistry)	University of Mumbai, India
1993-1995	M.S. (Chemistry)	Indian Institute of Technology (IIT), Mumbai, India
1995-2000	Ph.D. (Organic Chemistry)	Institute of Chemical Technology (ICT), Mumbai, India.

2. POSTDOCTORAL TRAINING

07/2000- 08/2003 Postdoctoral Fellow, Department of Pharmaceutical Sciences, School of Pharmacy,
University of Connecticut, Storrs, CT.

3. ACADEMIC APPOINTMENTS

09/2003-10/2004 Assistant Research Professor, Department of Pharmaceutical Sciences, School of
Pharmacy, University of Connecticut, Storrs, CT.

11/2004-06/2005 Senior Research Scientist, Center for Drug Discovery, NEU, Boston, MA, USA

07/2005- 08/2010 Assistant Research Professor, Center for Drug Discovery, NEU, Boston, MA, USA.

09/2010- 08/2016 Assistant Professor (Tenure-track), Department of Pharmaceutical Sciences,
Northeastern University, Boston, MA, USA.

09/2016 – 06/2021 Associate Professor (Tenured), Department of Pharmaceutical Sciences, Northeastern
University, Boston, MA, USA.

07/2017-06/2018 Vice Chair, Department of Pharmaceutical Sciences, Northeastern University, Boston,
MA.

07/2021- current Professor, Department of Pharmaceutical Sciences, Northeastern University, Boston,
MA, USA.

07/2018- 06/2020 Interim Chair, Department of Pharmaceutical Sciences, Northeastern University, Boston,
MA.

07/2020- current Chairman, Department of Pharmaceutical Science, Northeastern University, Boston,
MA.

4. AWARDS AND HONORS

- 1995 Recipient of Fellowship of University Grant Commission (UGC, India) as a Junior Research Fellow
- 1998 Recipient of Fellowship of University Grant Commission (UGC, India) as a Senior Research Fellow
- 1998 Recipient of “Best Paper Presentation Award” in XIVth Carbohydrate Conference Conducted by Indian Institute of Technology (IIT) in collaboration with Association of Carbohydrate Chemists & Technologists, India.
- 2009 Early Career Development Award in Chemistry of Drug Abuse and Addiction (ECHEM) from NIDA.
- 2011 Excellence in Teaching Award, School of Pharmacy, Northeastern University, Boston, MA 02115
- 2014 The Schumacher Award for Excellence in Research, Northeastern University, Boston, MA 02115
- 2015 RISE (Research, Innovation, Scholarship, and Expo) Award in Health Sciences, NEU, Boston, 2015 (Graduate Student: Abhijit Kulkarni)
- 2015 Nominated for Northeastern University’s University-wide “Excellence in Teaching Award.”
- 2015 Nominated for “Bouve College Distinguished Educator Award” for the year 2015.
- 2015 Guest Speaker, Rho Chi Society’s Annual Lecture Series, 2015.
- 2018 Best Patent Award from the Boston Patent Law Association (BPLA). Patent Title: Allosteric Modulators of CB1 Cannabinoid Receptor. *United States Patent #9,926,275 B2
- 2019 Excellence in Teaching Award, School of Pharmacy, Northeastern University, Boston, MA 02115
- 2022 RISE (Research, Innovation, Scholarship, and Expo) Award in Health Sciences, NEU, Boston, MA 02115 (Graduate Student: Lucas Cantwell)
- 2023 Hind Rattan Award, Given by the NRI Welfare Society of India
- 2023 Distinguished Mentor Award, Bouve College of Health Sciences, Northeastern University, Boston, MA.
- 2024 Invited Member, National Academy of Inventors, Northeastern Chapter.

5. IN NEWS/MEDIA:

- 1) “Last Dance with Mary Jane” <http://www.northeastern.edu/news/2014/03/thakur/>
- 2) “A Promising Alternative to Medical Marijuana:”
<http://www.northeastern.edu/news/2014/09/promising-alternative-medical-marijuana/>
- 3) “Smarten Up” <http://www.northeastern.edu/news/2014/03/smarten-up/>
- 4) “Local researchers work to eliminate high from medical marijuana”
<http://boston.cbslocal.com/tag/ganesh-thakur/>
- 5) “Hope the prescription can mimic marijuana’s benefits”
<https://www.bostonglobe.com/lifestyle/health-wellness/2014/11/17/some-parents-children-who-have-seizures-are-hoping-that-prescription-drug-will-able-mimic-marijuana-benefits/KoGizuhG99EO3w0RkyOrcO/story.html>
- 6) Discovering drug treatments for alcohol addiction (Project with an undergraduate student)
<https://news.northeastern.edu/2017/04/discovering-drug-treatments-for-alcohol-addiction/>

- 7) Novel Compound Alleviates Hard-to-Treat Pain in Mice (NIH Highlight)
<https://www.drugabuse.gov/news-events/nida-notes/2018/06/novel-compound-alleviates-hard-to-treat-pain-in-mice>
- 8) “The drug could stop the opioid epidemic”
<https://news.northeastern.edu/2018/12/05/this-drug-could-stop-the-opioid-epidemic/>
- 9) Will the new non-addictive painkiller approved by the FDA take the place of opioid drugs? Who should get a prescription?
<https://news.northeastern.edu/2025/01/31/non-addictive-painkiller-journavx/>

II. RESEARCH AND SCHOLARSHIP:

GOOGLE SCHOLR ANALYSIS: (as of 05/18/2025): **H-index = 43**; **i10-index = 106**; Total Citations = **5430**; Total publications = **123**; Book Chapters = **4**; Total patents = **9**.

A. PEER-REVIEWED PUBLICATIONS (IN CHRONOLOGICAL ORDER)

1. Rao, P. S., **Thakur, G.A.**, Lahiri, G. K., Synthesis, characterization and redox properties of ruthenium (II) phenolato Schiff base mixed ligand complexes. *Indian Journal of Chemistry, Sect. A: Inorganic, Bio-inorganic, Physical, Theoretical and Analytical Chemistry*, **1996**, 35A (11), 946-951.
2. Santra, B. K., **Thakur G. A.**, Ghosh, P., Pramanik, A., Lahiri, G. K., A novel example of metal-mediated aromatic thiolation in ruthenium complex: crystal structure of RuII (SC₆H₄N:NC₅H₄N)₂. *Inorganic Chemistry*, **1996**, 35(10), 3050-3052.
3. **Thakur, G. A.**, Narayanswami, K., Lahiri, G. K., Synthesis, characterization and redox properties of ruthenium (II) dithiocarbonato complexes having 2,2'-bipyridine co-ligands. *Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical and Analytical Chemistry*, **1996**, 35A (5), 379-384.
4. Nikas, S. P., **Thakur, G. A.**, Makriyannis, A., A convenient and effective synthesis of 3-(3,5-Dimethoxyphenyl)propanal. *Synthetic Communications*, **2002**, 32(11), 1751-1756.
5. Palmer, S., **Thakur, G. A.**, Makriyannis, A., Cannabinergic ligands. *Chemistry and Physics of Lipids*, **2002**, 121(1-2), 3-19.
6. Nikas, S. P., **Thakur, G. A.**, Makriyannis, A., Synthesis of side chain specifically deuterated(-)- Δ^9 -tetrahydrocannabinoids. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2002**, 45, 1-12.
7. Nikas, S. P., **Thakur, G. A.**, Makriyannis, A., Regiospecifically deuterated (-)- Δ^9 -tetrahydrocannabivarin. *J. Chem. Soc. Perkin. Trans.1*, **2002**, 22, 2544-2548.
8. **Thakur, G. A.**, Palmer, S., Harrington, P. E., Stergiades, I. A., Tius, M. A., Makriyannis, A., Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. *Journal of Biochemical and Biophysical Methods*, **2002**, 54(1-3), 415-422.

9. Lu, D., Meng, Z., **Thakur, G. A.**, Fan, P., Steed, J., Tartal, C. L., Hurst, D. P., Reggio, P. H., Deschamps, J. R., Parrish, D. A., George, C., Jarbe, T. U., Lamb, R. J., Makriyannis, A., Adamantyl Cannabinoids: A novel class of cannabinergic ligands. *Journal of Medicinal Chemistry*, **2005**, 48 (14), 4576-4585.
10. McLaughlin, P. J., Lu, D., Winston, K. M., **Thakur, G. A.**, Swezey, L. A., Makriyannis, A., Salamone, J. D., Behavioral effects of the novel cannabinoid CB1 agonist AM411. *Pharmacology Biochemistry and Behavior*, **2005**, 81(1), 78-88.
11. McLaughlin, P. J., Brown, C. M., Winston, K. M., **Thakur, G. A.**, Lu, D., Makriyannis, A., Salamone, J. D., The novel cannabinoid agonist AM 411 produces a biphasic effect on accuracy in a visual target detection task in rats. *Behavioral Pharmacology*, **2005**, 16(5-6), 477-486.
12. Picone, R. P., Khanolkar, A. D., Xu, W., Ayotte L. A., **Thakur, G. A.**, Hurst, D. P., Abood, M. E., Reggio, P. H., Fourier, D. J., Makriyannis, A., (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. *Molecular Pharmacology*, **2005**, 68 (6), 1623-1635.
13. **Thakur, G. A.**, Nikas, S. P., Makriyannis, A., CB1 Cannabinoid receptor ligands. *Mini Reviews in Medicinal Chemistry*, **2005**, 5(7), 631-640.
14. **Thakur, G. A.**, Duclos, R.I., Jr., Makriyannis, A., Natural cannabinoids: templates for drug discovery. *Life Sciences*, **2005**, 78(5), 454-466.
15. Pavlopoulos, S., **Thakur, G. A.**, Nikas, S. P., Makriyannis, A., Cannabinoid receptors as therapeutic targets. *Curr. Pharm. Design*, **2006**, 12(14), 1751-1769.
16. Kapur, A., Hurst, D. P., Fleischer, D., Whitnell, R., **Thakur, G. A.**, Makriyannis, A., Reggio, P. H., Abood, M. E., Mutation studies of Ser7.39 and Ser2.60 in the human CB₁ cannabinoid receptor: evidence for a serine induced bend in CB₁ transmembrane helix 7. *Molecular Pharmacology*, **2007**, 71(6), 1512-1524.
17. Nikas, S. P., **Thakur, G. A.**, Parrish, D. A., Alapafuja, S. O., Huestis, M., Makriyannis, A., A concise methodology for the synthesis of (-)- Δ^9 -tetrahydrocannabinol and (-)- Δ^9 -tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs. *Tetrahedron*, **2007**, 63, 8112-8123.
18. Khanolkar, A. D., Lu, D., Ibrahim, M., Duclos, R.I. Jr., **Thakur, G. A.**, Malan, T. P. Jr., Porreca, F., Veerappan, V., Tian, X., George, C., Parrish, D. A., Papahatjis, D. P., Makriyannis, A., Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. *Journal of Medicinal Chemistry*, **2007**, 50 (26), 6493-6500.
19. Sink, K.S., McLaughlin, P.J., Wood, J.A., Brown, C., Fan, P., Vemuri, V.K., Peng, Y., Olzewska, T., **Thakur, G.A.**, Makriyannis, A., Parker, L.A., Salamone, J.D., The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. *Neuropsychopharmacology*, **2008**, 33(4), 946-955.
20. Kapur, A., Samaniego, P., **Thakur, G. A.**, Makriyannis, A., Abood, M. E., Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 325 (1), 341-348.

21. Bergman, J., Delatte, M. S., Paronis, C. A., Vemuri, V. K., **Thakur, G. A.**, Makriyannis, A., Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. *Physiology & Behavior*, **2008**, 93(4-5), 666-670.
22. Rahn, E. J., Zvonok, A. M., **Thakur, G. A.**, Khanolkar, A. D., Makriyannis, A., Hohmann, A. G., Selective activation of cannabinoid CB₂ receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 327(2), 584-591.
23. Pei, Y., Mercier, R. W., Anday, J. K., **Thakur, G. A.**, Zvonok, A. M., Reggio, P. H., Janero, D. R., Makriyannis, A., Ligand-binding architecture of human CB₂ cannabinoid receptor: evidence for a receptor subtype-specific binding motif and modeling GPCR activation. *Chemistry & Biology*, **2008**, 15(11), 1207-1219.
24. Sink K. S., Segovia K. N., Nunes E. J., Collins L. E., Vemuri V. K., **Thakur G. A.**, Makriyannis A., Salamone J. D. Intracerebroventricular administration of cannabinoid CB₁ receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. *Psychopharmacology (Berl.)*, **2009**, 206(2), 223-232.
25. **Thakur GA***, Tichkule, R., Bajaj, S., Makriyannis, A. R Recent advances in cannabinoid receptor agonist. *Expert Opinion on Therapeutic Patents*. **2009**, 19 (12), 1647-73.
26. Dixon, D. D., Sethumadhavan, D., Benneche, T., Banaag, A. R., Tius, M. A., **Thakur, G. A.**, Bowman, A., Wood, J., Makriyannis, A. Heteroadamantyl Cannabinoids. *Journal of Medicinal Chemistry*, **2010**, 53(15), 5656-66.
27. Rahn, E., **Thakur, G. A.**, Zvonok, A. M., Vemuri, V. K., Makriaynnis, A., Hohmann, A. G., Pharmacological characterization of putative cannabinoid CB₂ agonist from the cannabilactone class: Antinociception without central nervous system side-effects. *Pharmacology, Biochemistry & Behavior*, **2011**, 98, 493-502.
28. Teng, H.¹, **Thakur, G. A.¹**, Makriyanis, A. Conformationally restricted analogs of BAY59-3074 as novel cannabinoid receptor ligands. *Bioorganic & Medicinal Chemistry Letters*, **2011**, 21, 5999-6002. (¹ Equal author contribution)
29. Szymanski, D. W., Papanastasiou, M., Melchior, K., Zvonok, N., Mercier, R. W., Janero, D. R., **Thakur, G. A.**, Cha, S., Wu, B., Karger, B., Makriyannis, A. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation, *Journal of Proteome Research*, **2011**, 10, 4789-4798.
30. Wilkerson, J.L., Gentry, K.R., Dengler, E.C., Wallace, J.A., Kerwin, A.A., Kuhn, M.N., Zvonok, A.M., **Thakur, G.A.**, Makriyannis, A., Milligan, E.D. Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. *Brain and Behavior*, **2012**, 2(2), 155-177.
31. Wilkerson, J.L., Gentry, K.R., Dengler, E.C., Wallace, J.A., Kerwin, A.A., Armijo, L.M., Kuhn, M.N., **Thakur, G.A.**, Makriyannis, A., Milligan, E.D., Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. *Pain*, **2012**, 153(5), 1091-1106.

32. Dixon, D.D., Tius, M.A., **Thakur, G.A.**, Zhou, H., Bowman, A.L., Shukla, V.G., Peng, Y., Makriyannis, A. C3-Heteroaryl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor. *Bioorganic & Medicinal Chemistry Letters*, **2012**, 22(16), 5322-5325.
33. Deng, L., Guindon, J., Vemuri, K.V., **Thakur, G.A.**, White, F.A., Makriyannis, A., Hohmann, A. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. *Molecular Pain*, **2012**, 8: 71.
34. Desai, R.V., **Thakur, G.A.**, Vemuri, K.V., Bajaj, S.B., Makriyannis, A., Bergman, A. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and non-cannabinoid drugs. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 344, 319-328.
35. Paronis, C.A., **Thakur, G.A.**, Bajaj, S.B., Nikas, S.P., Vemuri, K.V., Makriyannis, A., Bergman, J. Diuretic Effects of Cannabinoids. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 314, 8-14.
36. **Thakur, G.A.***, Bajaj, S.B., Paronis, C.A., Peng, Y., Bowman, A.L. Barak, L., Caron, M.G. Parrish, D.A., Deschamps, J., Makriyannis, A. Novel Adamantyl Cannabinoids as CB1 Receptor Probes, *Journal of Medicinal Chemistry*, **2013**, 6(10):3904-3921.
37. McLaughlin, P.J., **Thakur, G. A.**, McClure, E.D., Brown, C.M., Winston, K.M., Wood, J.T., Makriyannis, A., Salamone, J.D. Behavioral effects of the novel potent cannabinoid CB1 agonist AM4054, *Pharmacology Biochemistry and Behavior*. **2013**, 119:16-22.
38. Miller R.L., **Thakur G. A.**, Stewart W.N., Bow J.P., Bajaj S., Makriyannis A., McLaughlin P.J. Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy. *Experimental & Clinical Psychopharmacology* **2013**; 21(5):416-25.
39. Kangas BD, Delatte M.S., Vemuri V.K., **Thakur G.A.**, Nikas SP, Subramanian KV, Shukla VG, Makriyannis A, Bergman J. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. *Exp Clin Psychopharmacology*, **2013**, 344(3):561-567.
40. Chopda, G. R., Vemuri, V. K., Sharma, R., **Thakur, G.A.**, Makriyannis, A., Paronis, C.A. Diuretic effects of cannabinoid agonists in mice. *European Journal of Pharmacology*, **2013**; 721(1-3):64-69
41. Kulkarni AR, **Thakur G.A.***. Microwave-assisted Expeditious and Efficient Synthesis of Cyclopentene Ring-fused Tetrahydroquinoline Derivatives Using Three-component Povarov Reaction. *Tetrahedron Letters*, **2013**, 54(48), 6592-6595.
42. Papke RL, Horenstein NA, Kulkarni AR, Stokes C, Corrie LW, Maeng CY, **Thakur G.A.***. The activity of GAT107, an allosteric activator and positive modulator of $\alpha 7$ nAChR, is regulated by aromatic amino acids that span the subunit interface. *Journal of Biological Chemistry*, **2014**, 289(7), 4515-4517.
43. **Thakur G.A.***, Kulkarni AR, Deschamps JR, Papke RL. Expeditious Synthesis, Enantiomeric Resolution, and Enantiomer Functional Characterization of (4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): An Allosteric Agonist-Positive Allosteric Modulator of $\alpha 7$ Nicotinic Acetylcholine Receptors. *J. Med. Chem.* **2013**; 56(21):8943-8947.

44. Sharma R, Nikas SP, Paronis CA, Wood JT, Halikhedkar A, Guo JJ, **Thakur G.A.**, Kulkarni S, Benchama O, Raghav JG, Gifford RS, Järbe TU, Bergman J, Makriyannis A. Controlled-detoxification Cannabinergic Ligands. *Journal of Medicinal Chemistry*, **2013**, 56(24):10142-10157.
45. Gamage, T., Ignatowska-Jankowska, B. M., Abdelrahman, M., Trembleau. L., **Thakur, G. A.**, Tichkule, R. B. ; Poklis, J. ; Ross, R. A., Pertwee, R. G. and Lichtman, A. H. Investigation of the *in vivo* pharmacological effects of the CB1 receptor allosteric modulator Org-27569. *Behavioral Pharmacology*, **2014** Apr; 25(2):182-185.
46. Rahn, E.J., Deng, L., **Thakur, G.A.**, Vemuri, V.K., Zvonok, A. M., Lai, Y. Y. Makriyannis, A. and Hohmann, A.G. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery *Molecular Pain*. **2014**, 10(1):27; doi:10.1186/1744-8069-10-27.
47. Fichna, J., Bawa, M., **Thakur, G.A.**, Tichkule, R., Makriyannis, A., McCafferty, D.M., Sharkey, K.A., Storr, M. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. *PLoS One*. **2014** Oct 2;9(10): e109115.
48. Nikas, S.P., Sharma R, Paronis, C.A., Kulkarni, S., **Thakur G.A.**, Hurst, D., Wood, J.T., Gifford, R.S., Rajarshi, G., Liu, Y., Raghav, J.G., Guo, J.J., Järbe, T.U., Reggio, P.H., Bergman, J., Makriyannis, A. Probing the Carboxyester Side Chain in Controlled Deactivation (-)- Δ^8 -Tetrahydrocannabinols. *Journal of Medicinal Chemistry*. **2015**, 58(2), 665-681.
49. Keenan, C.M, Storr, M.A., **Thakur, G.A.**, Wood, J.T., Wager-Miller J., Straiker, A., Eno, M.R., Nikas S.P., Bashashati, M., Hu, H., Mackie, K., Makriyannis, A. and Sharkey, K.A. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally-restricted manner. *British Journal of Pharmacology*, **2015**, 172(9), 2406-2418.
50. Lee, W.H.; Xu, Z.; Ashpole, N.; Hudmon, A.; Kulkarni, P.M.; **Thakur, G.A.**; Lai, Y.; Hohmann, A.H. Small molecule inhibitors of protein-protein interaction as novel analgesics; *Neuropharmacology*, **2015**; 97:464-475.
51. Abalo, R.; Chen, C.; Vera, G.; Fichna, J.; **Thakur, G. A.**; López-Pérez, A. E., Makriyannis, A.; Martín-Fontelles, M. I.; Storr, M. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. *Neurogastroenterology and Motility*, **2015**, 27(12), 1721-1735.
52. Papke R.L., Bagdas, D., Kulkarni, A.R., Gould, T., AlSharari, S.D., **Thakur, G. A.**, Damaj, M. I. The analgesic-like properties of the $\alpha 7$ nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor. *Neuropharmacology*, **2015**; 91:34-42.
53. Kulkarni, P.M., Kulkarni, A.R., Korde A., Tichkule, R.B., Laprairie R.B., Denovan-Wright E.M., Zhou H., Janero D.R., Zvonok N., Makriyannis A., Cascio M.G., Pertwee R.G., **Thakur G.A.***. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). *Journal of Medicinal Chemistry*, **2016** ;59(1):44-60.
*This manuscript was highlighted as the Editor's choice article.
54. Horenstein, N.A., Papke, R.L., Kulkarni, A.R., Chaturbhuji, G.U., Stokes, C., Manther, K., **Thakur GA***. Critical Molecular Determinants of $\alpha 7$ Nicotinic Acetylcholine Receptor Allosteric Activation: Separation of Direct Allosteric Activation and Positive Allosteric Modulation. *Journal of Biological Chemistry*, **2016** Mar 4;291(10):5049-5067.

55. Laprairie, R.B., Kulkarni, A.R., Kulkarni, P.M., Hurst, D.P., Lynch, D., Reggio, P.H., Janero, D.R., Pertwee, R.G., Stevenson, L.A., Kelly, M.E., Denovan-Wright, E.M., **Thakur, G.A.***. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. *ACS Chemical Neuroscience*, **2016**;7(6):776-798.
56. Smith, A.E., Xu, Z., Lai, Y.Y., Kulkarni, P.M., **Thakur G.A.**, Hohmann A.G., Crystal J.D. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. *Behavioral Brain Research*, **2016**; 305:23-29.
57. Chopda, G.R., Parge, V., **Thakur, G.A.**, Gatley, S.J., Makriyannis, A., Paronis, C.A. Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to κ -Opioid Agonist in THC-Treated Mice. *Journal of Pharmacology and Experimental Therapeutics*. **2016**; 358(2):334-341.
58. Bagdas D.*, Wilkerson J.L., Kulkarni A., Toma W., AlSharari S., Gul Z., Lichtman A.H., Papke R.L., **Thakur G.A.***, Damaj M.I. The $\alpha 7$ nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain. *British Journal of Pharmacology*, **2016**,173(16):2506-2520.
59. Järbe, T.U., LeMay, B.J., **Thakur, G.A.**, Makriyannis, A. A high efficacy cannabinergics ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Δ^9 -THC in rats. *Pharmacology Biochemistry and Behavior*, **2016**; 148:46-52.
60. Janero D.R., **Thakur G.A.***. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. *Expert Opinion on Drug Discovery*, **2016**;11(12):1223-1237.
61. Kulkarni A.R., Garai S., **Thakur G.A.***. Scalable, One-Pot, Microwave-Accelerated Tandem Synthesis of Unsymmetrical Urea Derivatives. *Journal of Organic Chemistry*, **2017**; 82(2):992-999.
62. Laprairie R.B., Kulkarni P.M., Deschamps J.R., Kelly M.E.M., Janero D.R., Cascio M.G., Stevenson L.A., Pertwee R.G., Kenakin T.P., Denovan-Wright E.M., **Thakur GA***. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. *ACS Chemical Neuroscience*, **2017**, 8(6):1188-1203.
63. Zhou, H., Peng, Y., Halikhedkar, A., Fan, P., Janero, D.R., **Thakur, G.A.**, Mercier, R.W., Sun, X., Ma, X., Makriyannis, A. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. *ACS Chemical Neuroscience*, **2017**; 8(6):1338-1347.
64. Carey L.M., Lee W.H., Gutierrez T., Kulkarni P.M., **Thakur G.A.**, Lai Y.Y., Hohmann A.G. Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. *Neuroscience*. **2017**; 349:303-317.
65. Papke R.L., Stokes C., Damaj M.I., **Thakur G.A.**, Manther K., Treinin M., Bagdas D., Kulkarni A.R., Horenstein N.A. Persistent activation of $\alpha 7$ nicotinic ACh receptors associated with stable induction of different desensitized states. *Br. J. Pharmacol.* **2017** May 6. doi: 10.1111/bph.1385.

66. Donvito G., Bagdas D., Toma W., Rahimpour E., Jackson A., Meade J.A., AlSharari S., Kulkarni A.R., Ivy Carroll F., Lichtman A.H., Papke R.L., **Thakur G.A.**, Imad Damaj M. The interaction between $\alpha 7$ nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor- α represents a new antinociceptive signaling pathway in mice. *Experimental Neurology*, **2017**; 295:194-201.
67. Cairns, E.A., Szczesniak, A.M., Straiker, A.J., Kulkarni, P.M., Pertwee, R.G., **Thakur, G.A.**, Baldridge, W.H., Kelly, M.E.M. The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. *Journal of Ocular Pharmacology and Therapeutics*, **2017**, 33(8):582-590.
68. Kulkarni, P.M., Ranade, A., Garai, S., **Thakur, G.A.*** Microwave-accelerated Conjugate Addition of 2-Arylindoles to Substituted β -Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators, **2017**, 54, 2079-2084.
69. Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, **Thakur GA**, Hohmann AG. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. *Biological Psychiatry*. **2018**, 84(10):722-733.
70. Mitjavila J., Yin D., Kulkarni P.M., Zanato C., **Thakur G.A.**, Ross R., Greig I., Mackie K., Straiker A. Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. *Pharmacological Research*, **2018**, 129:475-481.
71. Shekhar, A., **Thakur, G.A.** Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder. *Neuropsychopharmacology*. **2018**, 43(1):226-227.
72. Ha, J., Xu Y., Kawano, T., Hendon, T., Baki, L., Garai, S., Papapetropoulos, A., **Thakur, G.A.**, Plant, L.D., Logothetis, D.E. Hydrogen sulfide inhibits Kir2 and Kir3 channels by decreasing sensitivity to the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2). *Journal of Biological Chemistry*, **2018**, 293(10):3546-3561.
73. Li, L.P., Dustrude, E.T., Haulcomb, M.M., Abreu, A.R., Fitz, S.D., Johnson, P.L., **Thakur, G.A.**, Molosh, A.I., Lai, Y., Shekhar, A. PSD95 and nNOS interaction as a novel molecular target to modulate conditioned fear: relevance to PTSD. *Translational Psychiatry*, **2018**, 8(1):155.
74. Salaga M., Binienda A., Tichkule R.B., **Thakur G.A.**, Makriyannis A., Storr M., Fichna J. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. *European Journal of Pharmacology*, **2018** Oct 5; 836:34-43.
75. Garai, S., Raja, K.S., Papke, R.L., Deschamps, J.R., Damaj, M.I., **Thakur, G.A.*** B-973, a Novel $\alpha 7$ nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and *in Vivo* Evaluation. *ACS Medicinal Chemistry Letters*, **2018** Oct 11;9(11):1144-1148.
76. Quadri M., Garai S., **Thakur G.A.**, Stokes C., Gulsevin A., Horenstein N.A., Papke R.L. Macroscopic and Microscopic Activation of $\alpha 7$ Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. *Molecular Pharmacology*. **2019**, 95(1):43-61.

77. Pan, J., Mendes, L.P., Yao M., Filipczak, N., Garai, S., **Thakur, G.A.**, Sarisozen, C., Torchilin, V.P. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 136:18-28.
78. Laprairie, R.B., Bagher, A.M., Rourke, J.L., Zrein, A., Cairns, E.A., Kelly, M.E.M, Sinal, C.J., Kulkarni, P.M., **Thakur G.A.**, Denovan-Wright, E.M. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. *Neuropharmacology*. **2019**, 151:1-12.
79. Gulsevin, A., Papke, R.L., Stokes, C., Garai, S., **Thakur, G.A.**, Quadri M., Horenstein, N.A. Allosteric Agonism of $\alpha 7$ Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site. *Molecular Pharmacology* **2019**, 95(6):606-614.
80. Stokes, C., Garai, S., Kulkarni, A.R., Cantwell, L.N., Noviello, C.M., Hibbs, R.E., Horenstein, N.A., Abboud, K.A., **Thakur, G.A.**, Papke, R.L. Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to $\alpha 7$ -Selective Positive Allosteric Modulators. *Journal of Pharmacology and Experimental Therapeutics*. **2019** Aug; 370(2):252-268.
81. Toma, W., Kyte, S.L., Bagdas, D., Jackson, A., Meade, J.A., Rahman, F., Chen, Z.J., Del Fabbro, E., Cantwell, L., Kulkarni A., **Thakur G.A.**, Papke R.L., Bigbee J.W., Gewirtz D.A., Damaj M.I. The $\alpha 7$ nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. *Experimental Neurology*, **2019** Oct; 320:113010.
82. Hurst, D.P., Garai, S., Kulkarni, P.M., Schaffer, P.C., Reggio, P.H., **Thakur, G.A.***. Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies. *ACS Medicinal Chemistry Letters*, **2019**, 10(8):1216-1221.
83. Laprairie R.B., Mohamed K.A., Zagzoog A, Kelly M.E.M., Stevenson L.A., Pertwee R., Denovan-Wright E.M., **Thakur G.A.***. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. *Frontiers in Molecular Neuroscience*, **2019** Oct 18; 12:257.
84. Garai S., Kulkarni P.M., Schaffer P.C., Leo L.M., Brandt A.L., Zagzoog A., Black T., Lin X., Hurst D.P., Janero D.R., Abood M.E., Zimmowitch A., Straiker A., Pertwee R.G., Kelly M.E.M., Szczesniak A.M., Denovan, E.M., Mackie K., Hohmann A.G., Reggio P.H., Laprairie R.B., **Thakur G.A.*** Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. *Journal of Medicinal Chemistry*, **2020**, 63(2), 542-568.
85. Thapa, D., Cairns, E.A., Szczesniak, A.M., Kulkarni, P.M., Straiker, A.J., **Thakur, G.A.**, Kelly, M.E.M., Allosteric cannabinoid receptor 1 (CB1) ligands reduce ocular pain and inflammation. *Molecules* **2020**, 20; 25(2):417.
86. Slivicki, R.A., Iyer, V., Mali, S.S., Garai, S., **Thakur, G. A.** and Hohmann, A.G., Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without altering morphine-induced dependence or reward. *Frontiers in Molecular Neuroscience*, **2020**, 28;13:54.

87. Xu, Y., Cantwell, L., Molosh, A.I., Plant, L.D., Gazgalis, D., Fitz, S.D., Dustrude, E.T., Yang, Y., Kawano, T., Garai, S., Noujaim, S.F., Shekhar, A.,*, Logothetis, D.E.,*, and **Thakur, G.A.***. The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents. *Journal of Biological Chemistry*, **2020**,13;295(11):3614-3634.
88. Ben-David, Y., Kagan, S., Ben-Ami, H.C., Rostami, J., Mizrachi, T., Kulkarni, A.R., **Thakur, G.A.**,; Vaknin-Dembinsky, A., Healy, L., Brenner, T., Treinin, M. RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammation *International Immunopharmacology*, **2020** Jun; 83:106381.
89. Papke R.L.*, Garai S, Stokes C, Horenstein NA, Zimmerman AD, Abboud KA, **Thakur G.A.*** Differing activity profiles of the stereoisomers of 2,3,5,6TMP-TQS, a putative silent allosteric modulator of $\alpha 7$ nAChR. *Molecular Pharmacology*, **2020**, 98(4), 292-302.
90. Schaffer, P.C., Kulkarni, P.M., Janero, D.R., **Thakur, G.A.*** Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. *Bioorganic and Medicinal Chemistry*, **2020**, 28(11), 115727.
91. Wilkerson, J.L., Alberti, L.B., Kerwin, A.A., Ledent, C.A., **Thakur, G.A.**, Makriyannis, A., and Milligan, E.D. Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain. *Brain and Behavior*. **2020**, Sep 25;e01850. doi: 10.1002/brb3.1850.
92. Timothy J. Onofrychuk, Shuang Cai, Dan L. McElroy, Andrew J. Roebuck, Quentin Greba, Sumanta Garai, **Ganesh A. Thakur**, Robert B. Laprairie, John G. Howland. Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2020 2021 Jul 13;109:110235. doi:10.1016/j.pnpbp.2020.110235. Epub 2020 Dec 26. PMID: 33373679.
93. Schaffer PC, Kulkarni PM, Janero DR, **Thakur, G.A.** Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. *Bioorg Med Chem*. **2020** Nov 1;28(21):115727. doi: 10.1016/j.bmc.2020.115727. Epub 2020 Aug 29. PMID: 33065437
94. Papke RL, Garai S, Stokes C, Horenstein NA, Zimmerman AD, Abboud KA, **Thakur GA.** Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of $\alpha 7$ nAChR. *Mol Pharmacol*. **2020** Oct;98(4):292-302. doi: 10.1124/mol.120.119958. Epub 2020 Jul 20. PMID: 32690627; PMCID: PMC7472127.
95. Ben-David, Y., Kagan, S., Cohen, Ben-Ami H., Rostami, J., Mizrahi, T., Kulkarni, A.R., **Thakur, G.A.**, Vaknin-Dembinsky A, Healy, L.M., Brenner, T., Treinin, M. RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammation. *Int Immunopharmacol*. **2020** Jun;83:106381. doi: 10.1016/j.intimp.2020.106381. Epub **2020** Mar 14. PMID: 32179243.
96. Thapa D, Cairns EA, Szczesniak AM, Kulkarni PM, Straiker AJ, **Thakur G.A.**, Kelly MEM. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. *Molecules*. 2020 Jan 20;25(2):417. doi: 10.3390/molecules25020417. PMID: 31968549; PMCID: PMC7024337.

97. Xu Y, Cantwell L, Molosh AI, Plant LD, Gazgalis D, Fitz SD, Dustrude ET, Yang Y, Kawano T, Garai S, Noujaim SF, Shekhar A, Logothetis DE, **Thakur, G.A.** The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents. *J Biol Chem.* 2020 Mar 13;295(11):3614-3634. doi: 10.1074/jbc.RA119.011527. Epub 2020 Jan 17. PMID: 31953327; PMCID: PMC7076198.
98. Dan L. McElroy, Andrew J. Roebuck, Gavin A. Scott, Quentin Greba, Garai S., Eileen M. Denovan-Wright, **Ganesh A. Thakur**, Robert B. Laprairie, John G. Howland. Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. *Psychopharmacology.* (Berl). 2021 Apr;238(4):1087-1098. doi: 10.1007/s00213-020-05755-x. Epub 2021 Jan 13. PMID: 33442771
99. Gauthier AG, Wu J, Lin M, Sitapara R, Kulkarni A, **Thakur, G.A.**, Schmidt EE, Perron JC, Ashby CR Jr, Mantell LL. The Positive Allosteric Modulation of $\alpha 7$ -Nicotinic Cholinergic Receptors by GAT107 Increases Bacterial Lung Clearance in Hyperoxic Mice by Decreasing Oxidative Stress in Macrophages. *Antioxidants* (Basel). 2021 Jan 19;10(1):135. doi: 10.3390/antiox10010135. PMID: 33477969
100. Cui M, Alhamshari Y, Cantwell L, Ei-Haou S, Eptaminitaki GC, Chang M, Abou-Assali O, Tan H, Xu K, Masotti M, Plant LD, **Thakur, G.A.**, Noujaim SF, Milnes J, Logothetis DE. A benzopyran with antiarrhythmic activity is an inhibitor of Kir3.1-containing potassium channels. *J Biol Chem.* 2021 Jan-Jun;296:100535. doi: 10.1016/j.jbc.2021.100535. Epub 2021 Mar 11. PMID: 33713702
101. Jiang S, Iliopoulos-Tsoutsouvas C, Tong F, Brust CA, Keenan CM, Raghav JG, Hua T, Wu S, Ho JH, Wu Y, Grim TW, Zvonok N, **Thakur, G.A.**, Liu ZJ, Sharkey KA, Bohn LM, Nikas SP, Makriyannis A. Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. *J Med Chem.* 2021;64(7):3870-3884. doi: 10.1021/acs.jmedchem.0c02053.. PMID: 33761251
102. Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, **Thakur, G.A.** Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. *J Med Chem.* 2021 Jun 24;64(12):8104-8126. doi: 10.1021/acs.jmedchem.1c00040. PMID: 33826336
103. Roebuck, A., Greba, Q., Smolyakova, A., Alaverdashvili, M., Marks, W., Garai, S., Baglot, S., Petrie, G., Cain, S., Snutch, T., **Thakur, G.A.**, Hill, M.A., Howland, J., and Laprairie, R. Positive allosteric modulation of type 1 cannabinoid receptors reduces absence seizures in Genetic Absence Epilepsy Rats from Strasbourg. *Neuropharmacology.* 2021 Jun 1;190:108553. doi: 10.1016/j.neuropharm.2021.108553. Epub 2021 Apr 9. PMID: 33845076
104. Hamouda AK, Bautista MR, Akinola LS, Alkhlaif Y, Jackson A, Carper M, Toma WB, Garai S, Chen YC, **Thakur GA**, Fowler CD, Damaj MI. Potentiation of $(\alpha 4)2(\beta 2)3$, but not $(\alpha 4)3(\beta 2)2$, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms. *Neuropharmacology.* 2021 Jun 1;190:108568. PMID: 33878302
105. Mizrachi T, Marsha O, Brusin K, Ben-David Y, **Thakur G.A.**, Vaknin-Dembinsky A, Treinin M, Brenner T. J. Suppression of neuroinflammation by an allosteric agonist and positive allosteric

- modulator of the $\alpha 7$ nicotinic acetylcholine receptor GAT107. *Neuroinflammation*. **2021** Apr 26;18(1):99. PMID: 33902624
106. Pismataro MC, Horenstein NA, Stokes C, Dallanoe C, **Thakur GA**, Papke RL. Stable desensitization of $\alpha 7$ nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. *Eur J Pharmacol*. **2021** Aug 15;905:174179. PMID: 34004208
107. Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, **Thakur, G.A.** Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. *Bioorg Med Chem*. **2021** Nov 15;50:116421. doi: 10.1016/j.bmc.2021.116421. Epub 2021 Sep 25. PMID: 34634617
108. Wilkerson JL, Alberti LB, **Thakur GA**, Makriyannis A, Milligan ED. Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG. *Brain Res*. **2022** Jan 1;1774:147721. PMID: 34774500
109. Anderson LL, Doohan PT, Hawkins NA, Bahceci D, Garai S, **Thakur, G.A.**, Kearney JA, Arnold JC. The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. *Neuropharmacology*. **2021** Nov 22;205: 108897. PMID: 34822817
110. Dan L McElroy, Andrew J Roebuck, Quentin Greba, Sumanta Garai, Asher L Brandt, Orhan Yilmaz, Stuart M Cain, Terrance P Snutch, **Ganesh A Thakur**, Robert B Laprairie, John G Howland. The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. *IBRO Neurosci Rep*. 2022 Jan 24;12:121-130. PMID: 35128516 PMCID: PMC8804275
111. Oliva, I., Saberi, S.A., Rangel-Barajas, C., Iyer, V., Bunner, K.D., Lai, Y.Y., Kulkarni, P.M., Garai, S., **Thakur, G.A.**, Crystal, J.D., Rebec, G.V., Hohmann, A.G. Inhibition of PSD95-nNOS protein-protein interactions decreases morphine reward and relapse vulnerability in rats. *Addict. Biol.*, 2022 Sep;27(5):e13220.
112. Gazgalis, D., Cantwell, L., Xu, Y., **Thakur, G.A.**, Cui, M., Guarnieri, F., Logothetis, D.E., Use of a Molecular Switch Probe to Activate or Inhibit GIRK1 Heteromers In Silico Reveals a Novel Gating Mechanism. *Int. J. Mol. Sci*. **2022** Sep 16;23(18):10820. doi: 10.3390/ijms231810820. PMID: 36142730 PMCID: PMC9502415
113. Iyer V, Rangel-Barajas C, Woodward TJ, Kulkarni A, Cantwell L, Crystal JD, Mackie K, Rebec GV, **Thakur G.A.**, Hohmann AG. Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated reward. *Pharmacol Res*. **2022** Nov;185:106474. PMID: 36179954
114. Stokes C, Camacho-Hernandez GA, **Thakur GA**, Wu X, Taylor P, Papke RL. Differential Activation and Desensitization States Promoted by Noncanonical $\alpha 7$ Nicotinic Acetylcholine Receptor Agonists. *J Pharmacol Exp Ther*. **2022** Nov;383(2):157-171. PMID: 36279397
115. Brandt AL, Garai S, Zagzoog A, Hurst DP, Stevenson LA, Pertwee RG, Immler GH, Reggio PH, **Thakur, G.A.**, Laprairie RB. Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593. *Front Pharmacol*. **2022** Oct 25;13:919605 PMID: 36386195

116. Gauthier AG, Lin M, Zefi S, Kulkarni A, **Thakur, G.A.**, Ashby CR Jr, Mantell LL. GAT107-mediated $\alpha 7$ nicotinic acetylcholine receptor signaling attenuates inflammatory lung injury and mortality in a mouse model of ventilator-associated pneumonia by alleviating macrophage mitochondrial oxidative stress via reducing MnSOD-S-glutathionylation. *Redox Biol.* **2023** Apr;60:102614. PMID: 36717349
117. Berms, B, M., Sullivan, E.E., Connolly, J.G., Zhang, J., Chang, A., Ortiz, R., Cantwell, L., Kulkarni, P., **Thakur, G.A.**, Ferris, C. F. Dose-dependent effects of GAT107, a novel allosteric agonist-positive allosteric modulator (ago-PAM) for the $\alpha 7$ nicotinic cholinergic receptor: a BOLD phMRI and connectivity study on awake rats. *Front Neurosci*, **2023**;17:1196786. doi: 10.3389/fnins.2023.1196786. eCollection 2023.
118. Dallanocce, C.; Richter, K.; Stokes, C.; Papotto, C.; Andleeb, H.; **Thakur, G. A.**; Kerr, A.; Grau, V.; Papke, R. L. New Alpha9 nAChR Ligands Based on a 5-(Quinuclidin-3-ylmethyl)-1,2,4-oxadiazole Scaffold. *ACS Chem Neurosci* **2024**, 15 (4), 827-843. DOI: 10.1021/acschemneuro.3c00720
119. Iyer, V.; Saberi, S. A.; Pacheco, R.; Sizemore, E. F.; Stockman, S.; Kulkarni, A.; Cantwell, L.; **Thakur, G. A.**; Hohmann, A. G. Negative allosteric modulation of cannabinoid CB (1) receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. *Neuropharmacology*. **2024**; 257:110052. doi: 10.1016/j.neuropharm.2024.110052. PMID: 38936657
120. Oliva, I.; Kazi, F.; Cantwell, L. N.; **Thakur, G. A.**; Crystal, J. D.; Hohmann, A. G. Negative allosteric modulation of CB1 cannabinoid receptor signaling decreases intravenous morphine self-administration and relapse in mice. *Addict Biol.* **2024** Aug;29(8):e13429. doi: 10.1111/adb.13429.
121. Burke, S. M.; Avstrikova, M.; Noviello, C. M.; Mukhtasimova, N.; Changeux, J. P.; **Thakur, G. A.**; Sine, S. M.; Cecchini, M.; Hibbs, R. E. Structural mechanisms of alpha7 nicotinic receptor allosteric modulation and activation. *Cell*, **2024**, 187 (5), 1160-1176 e1121. DOI: 10.1016/j.cell.2024.01.032
122. Andleeb, H. P., R.L.; Stokes, C.; Richter, K.; Herz, S.M.; Chiang, K.; Kanumuri, S.R.R.; Sharma, A.; Damaj, M.I.; Grau, V.; Horenstein, N.A.; **Thakur, G. A.*** **2024** Explorations of agonist selectivity for the $\alpha 9^*$ nAChR with novel substituted carbamoyl/amido/heteroaryl dialkylpiperazinium salts and their therapeutic implications in pain and inflammation. *J Med Chem.* **2024**;67(11):8642-8666. doi: 10.1021/acs.jmedchem.3c02429
123. Gaona, J., Gadekar, P.K., Abdelwahed, K.S., Sanchez, N.E., Rolling, A., Beaudoin, R., Bill, B., Kerr, A. T., **Thakur, G.A.**, Hamouda, A. K. Enantiospecific Positive Allosteric Modulation of $\alpha 4\beta 2$ Nicotinic Receptor Subtypes. *ACS Chem Neurosci.* **2025** Apr 29. doi: 10.1021/acschemneuro.5c00115. Online ahead of print.

B. BOOK CHAPTERS:

- 1) **Thakur, G. A.**, Nikas, S. P., Li, C., Makriyannis, A., Structural requirements for cannabinoid receptor probes. *Handbook of Experimental Pharmacology*, **2005**, 168, 209-246.
- 2) **Thakur, G. A.**, Nikas, S. P., Duclos, R. I., Jr., Makriyannis, A. Methods for the synthesis of cannabinergic ligands. *Methods in Molecular Medicine*, **2006**, 123, 113-148.

- 3) Kulkarni A.R., Garai S., Janero D.R., **Thakur G.A.***. Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications. *Methods Enzymol.* **2017**; 593:281-315.
- 4) Garai, S. and **Thakur, G.A.*** Copper-assisted Cyanation Reactions, Garai In *Copper Catalysis in Organic Synthesis*, Wiley-VCH, 2020.

C. PATENTS:

1. Alexandros Makriyannis, Spyros P. Nikas, Atmaram Khanolkar, **Ganesh A. Thakur** and Dai Lu, (2007) Methods of preparations and use of novel bicyclic cannabinoids, PCT Int. Appl. U.S. Patent Application No. 10/483,482, US 2007135388.
2. Alexandros Makriyannis, **Ganesh A. Thakur**, Rishi Sharma. Cannabinoids with controlled detoxification (US19539292, August 2012)
3. Alexandros Makriyannis, Marsha D'Souza, Shama Bajaj, Spyros Nikas, **Ganesh A. Thakur** Novel resorcinol derivatives as cannabinergic ligands. Application No.61714914, October 2012.
4. **Ganesh A. Thakur** and Pushkar M. Kulkarni, Allosteric Modulators of CB1 Cannabinoid Receptor, PCT/US13/20543; Filed January 7, 2013 (provisional date: January 2012)
5. **Ganesh A. Thakur**, Ritesh, B. Tichkule, Pushkar M. Kulkarni, Abhijit R. Kulkarni "Allosteric Modulators of CB1 Cannabinoid Receptor" PCT/US2014/052304, Date of Filing: August 22, 2014 (Provisional Date: August 22, 2013)
6. **Ganesh A. Thakur**, Abhijit R. Kulkarni and Roger L. Papke. "Novel Ligands for the $\alpha 7$ Nicotinic Acetylcholine Receptors" US Provisional Application No. 62/028, Date of Filing: July 23, 2014
7. **Ganesh A. Thakur**, Diomedes Logothetis, Anantha Shekhar, Lucas Cantwell. "Compounds for the Treatment of Post-Traumatic Stress Disorder" US Provisional Application No. 62683424, Date of Filing: June 11, 2018.
8. **Ganesh A. Thakur** & Sumanta Garai. "*N*-Substituted Indoles and Use as Allosteric Modulators of Cannabinoid Receptors". PCT Application No. PCT/US2019/039354. Date of filing June 26, 2019.
9. **Ganesh A. Thakur** & Hina Andleeb. "Novel alpha 9/alpha10 and alpha7 nicotinic acetylcholine receptor ligands". Provisional Patent Application filed on May 3, 2024

D. CONFERENCES

1. Synthesis of tetrasaccharide of Erylusamine-B, by **Ganesh A. Thakur** and K.G. Akamanchi. presented in XIIIth Carbohydrate Conference, conducted by Forest Research Institute in collaboration with Association of Carbohydrate Chemists & Technologist, India in Nov. 1998.
2. A novel catalytic approach for selective anomeric deacetylation of per-O-acetylated aldoses, by **Ganesh A. Thakur** and K.G. Akamanchi, in XIVth Carbohydrate Conference conducted by Indian Institute of Technology in collaboration with Association of Carbohydrate Chemists & Technologists, India in Dec-1999.
3. Selective anomeric deacetylation of per-O-acetylated aldoses by catalytic iodine in methanol, by **Ganesh A. Thakur** and K.G. Akamanchi, International Conference on Chemistry and 36th Annual

Convention of Chemists conducted by Indian Chemical Society and Indian Association for Cultivation of Sciences (IACS) in Calcutta, India, in Dec.1999.

4. Hypervalent iodine compound mediated bromoacetoxylation of olefinic natural products, by Sachin S. Chaudhari, G.V. Ramanarayanan, **Ganesh A. Thakur** and K. G. Akamanchi, 5th IUPAC International Symposium on Bioorganic Chemistry, conducted by International Union of Pure and Applied Chemistry at National Chemical Laboratory, Pune, India in Jan-Feb 2000.
5. Total Synthesis of Erylusamine-B - A potent Interleukin-6 Antagonist, by **Ganesh A. Thakur**, Smita G. Kavishwar and K.G. Akamanchi, 5th IUPAC International Symposium on Bioorganic Chemistry, conducted by International Union of Pure and Applied Chemistry at National Chemical Laboratory, Pune, India in Jan-Feb 2000.
6. New efficient synthesis of deuterated 5-alkylresorcinols and their application in the preparation of Δ^9 -THC, Δ^9 -THCV, and their metabolites by Spyros Nikas, **Ganesh A. Thakur**, Alexandros Makriyannis, in 222nd ACS National Meeting, Chicago, IL, United States, Aug. 2001.
7. Adamantyl cannabinoids, by Dai Lu, **Ganesh A. Thakur**, Peter J. McLaughlin, Lynn A. Swezey, Keisha M. Winston, Ania Wisniecki, John D. Salamone, Toby U. C. Jarbe, Patricia H. Reggio, Clifford George, Alexandros Makriyannis, 13th Annual International Cannabinoid Research Society (ICRS) Symposium, Cornwall, Ontario, Canada, June 2003.
8. A comparison of the novel CB1 agonist AM411 with the muscarinic antagonist Scopolamine a spatial discrimination task in rats by P. J. McLaughlin, K. M. Winston, L. A. Swezey, D. Lu, **G. A. Thakur**, A. Makriyannis, J. D. Salomone, Washington, DC: Society for neuroscience, 2004.
9. Some behavioral effects of the novel CB1-receptor agonist AM 411 in squirrel monkeys, by M. S. Delatte, M. Zielstroff, **G. Thakur**, A. Makriyannis, and J. Bergman, CPDD 67th annual meeting, Orlando, FL, June 18-23, 2005. McLean Hospital, Belmont, MA and University of Connecticut, Storrs, CT.
10. Synthesis and SAR of CB1 selective classical/non-classical hybrid cannabinoids, **Ganesh A. Thakur** and Alexandros Makriyannis, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005.
11. A ligand based structural biology approach for the characterization of the cannabinoid receptor binding domains, by John Williamns, Suma Yaddanapudi, Wei Xu, **Ganesh A. Thakur**, Nikolai Zvonok, Paul Vouros, Alexandros Makriyannis, 54th ASMS Conference on mass Spectrometry, in May-June 2006, Seattle, Washington. *FASEB J.* 2007 21:631.6.
12. Physiological and behavioral effects of novel CB1-receptor agonists AM 411 and AM 4054 in monkeys, by M.S. Delatte, **G.A. Thakur**, M. Riolo, A. Makriyannis and J. Bergman, Experimental Biology (Advancing the biomedical frontier), San Francisco, California, April 1-5, 2006.
13. Physiological and behavioral effects of novel CB1-receptor agonists AM 411 and AM 4054 in monkeys, by Marcus S Delatte, **G.A. Thakur**, Matthew Riolo, Alexandros Makriyannis, and Jack Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May2, 2007 *FASEB J.* 2006 20:A682.
14. Discriminative stimulus effects of methamphetamine and in vivo microdialysis in rat, by R. I. Desai, C. A. Paronis, A. Makriyannis, **G. A. Thakur**, and J. Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May2, 2007, *FASEB J.* 2007 21:715.3

15. Partial agonist and antagonist effects of Δ^9 -tetrahydrocannabinol (Δ^9 THC) in Rats, by Carol A Paronis; **Ganesh A Thakur**; Kiran Vemuri; Alex Makriyannis; Jack Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May2, 2007, *FASEB J.* 2007 21:562.2
16. Effects of a Selective Cannabinoid Agonist and Antagonist on Body Temperature in Rats, by Carol A Paronis; **Ganesh A Thakur**; Kiran Vemuri; Alex Makriyannis; Jack Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May 2, 2007, *FASEB J.* 2007 21:562.1
17. Synthesis of (-)- Δ^9 -tetrahydrocannabinol and (-)- Δ^9 -tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs, by Nikas, Spyros P.; **Thakur, Ganesh A.**; Parish, Damon; Alapafuja, Shakiru O.; Huestis, Marilyn A.; Makriyannis, Alexandros. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007, MEDI-031
18. Diuretic effect of cannabinoid agonists, by Carol A. Paronis, J. Martin, J. Bergman, **G. A. Thakur**, A. Zvonok and A. Makriyannis 12th European Behavioural Pharmacology Society, Tübingen, Germany, Aug 31-Sept 03, 2007.
19. New and efficient synthesis of regiospecifically deuterated covalent probes for cannabinoid receptors, by **Thakur Ganesh A.**; Sharma, Rishi; Makriyannis, Alexandros, 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI 63.
20. Hybrid adamantyl cannabinoids by Bajaj, Shama; **Thakur G.A.**; Tichkule, Ritesh; Makriyannis, Alexandros, 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI-370.
21. Structure activity relationship study of BAY 59-3074, a partial agonist of the CB1 cannabinoid receptor by Teng, Heidi; **Thakur, Ganesh A.**; Makriyannis, Alexandros. 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI-353.
22. Conformationally constrained analogs of BAY 59-3074, a CB1 cannabinoid receptor partial agonist by Teng, Heidi; **Thakur, G. A.**, Makriyannis, Alexandros. 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI-216.
23. The cannabinoid-1 (CB1) agonist AM841 slows GI motility in the rat by peripheral actions. *R. Abalo*, C. Chen, G Vera, M.A. Castillo, J. Fichna, **G.A. Thakur**, A. Makriyannis, M.I. Martín, M Storr. Neurogastroenterology and Motility Joint International meeting (NGM), August 26-29, 2010 Boston, MA.
24. Cannabinoid CB2 receptors activation suppresses neuropathic pain evoked by the chemotherapeutic agent cisplatin in rats by Josée Guindon, Spyridon Nikas, **Ganesh A. Thakur**, V. Kiran Vemuri, Alexandros Makriyannis and Andrea G. Hohmann. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
25. Intrathecal cannabinoid receptor 2 (CB2) agonists alter spinal and dorsal root ganglion inflammatory factors in neuropathic rats, by Jenny L. Wilkerson, Ellen C. Dengler, James A. Wallace, Audra A. Kerwin, **Ganesh A. Thakur**, Alexandros Makriyannis, and Erin D. Milligan. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
26. Amino acids D2.63 and K373 are important for maintaining the CB1R binding pocket, while residues K3.28 and S1.39 are involved in selective ligand recognition, by Jahan P. Marcu, Ankur Kapur, Megan Trznadel, Patricia H. Reggio, **Ganesh A. Thakur**, Alexandros Makriyannis, and Mary E. Abood. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.

27. Cannabinoid and κ -opioid mediated diuresis in rats, by Carol A. Paronis, **Ganesh A. Thakur**, and Alexandros Makriyannis. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
28. Diuresis: a simple and efficient measure to screen cannabinoids, by Girish R Chopda, Joseph B Anderson, **Ganesh A Thakur**, Alexandros Makriyannis, and Carol A Paronis. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
29. The selective cannabinoid receptor 2 (CB₂R) agonist AM1710 acts independently of cannabinod receptor 1 (CB₁R) responses in neuropathic mice. Jenny L. Wilkerson, Ellen C. Dengler, James A. Wallace, Audra A. Kerwin, Lauren B. Alberti, Brandi Bowman, Pamela S. Platero, **Ganesh A. Thakur**, Alexandros Makriyannis, Erin D. Milligan. Society of Neuroscience meeting, Washington, D.C., USA, November 12-16, 2011.
30. Selective activation of cannabinoid CB₂ receptors suppresses chemotherapy-induced neuropathy independent of CB₁ or CXCR4 receptor signaling. Deng, L., Guindon, J., Makie, K., White, F., **Thakur, G.A.**, Makriyannis, A., and Hohmann, A.G. 22nd Annual symposium of the International Cannabinoid Research Society, Freiburg, Germany, July 22-27, 2012.
31. Selective activation of cannabinoid CB₂ receptors suppresses the maintenance of chemotherapy-induced neuropathy and is independent of CB₁ signaling. Deng, L., Guindon, J., **Thakur, G.A.**, Makriyannis, A., Mackie, K., and Hohmann, A.G. Society for Neuroscience, 2012.
32. Positive Allosteric Modulators of CB₁ as Pharmacotherapy of Anorexia Nervosa. Kulkarni, P. M., Jarbe, T.U., Goldberg, S., Barbarich-Marsteller, N., **Thakur, G. A.**, RISE, NEU, Boston, 2013
33. Identification of a Potent Modulator of Nicotinic α 7Acetylcholine Receptors for the Treatment of Cognitive Disorders. Kulkarni, A. R., Deschamps, J.R., Papke R.L and **Thakur, G. A.** RISE, Northeastern Univ. Boston, March 22nd, 2013
34. Novel positive allosteric modulators of CB₁ cannabinoid receptor for the treatment of anorexia nervosa By Kulkarni, Pushkar M.; Jarbe, Torbjorn; Goldberg, Steven; Barbarich-Marsteller, Nicole r; **Thakur, Ganesh A.** From Abstracts of Papers, 246th ACS National Meeting & Exposition, Indianapolis, IN, United States, September 8-12, 2013 (2013), MEDI-84.
35. Stereochemical requirements within the tetrahydroquinoline scaffold for the positive allosteric modulation at α 7 nicotinic acetylcholine receptors. Kulkarni, Abhijit R.; Deschamps, Jeffrey; Papke, Roger L.; **Thakur, Ganesh A.** From Abstracts of Papers, 246th ACS National Meeting & Exposition, Indianapolis, IN, United States, September 8-12, 2013 (2013), MEDI-83.
36. Mutations of α 7 nAChR W55 enhance the allosteric agonism of GAT107, the active isomer of 4BP-TQS, and decouple interactions between orthosteric and allosteric sites. R. L. Papke, N. A. Horenstein, C. Stokes, Cheol-Young Maeng, A. R. Kulkarni, and **G. A. Thakur**, Society for Neuroscience, New Orleans, LA, November 10, 2013.
37. Modifying CB₁ receptor signaling to reduce IOP in a mouse model of ocular hypertension. Elizabeth A. Cairns, Michele L. Archibald, Alex J. Straiker, Pushkar M. Kulkarni, **Ganesh A. Thakur**, William H. Badridge and Melanie E.M. Kelly, International Cannabinoid Research Society (ICRS), Braveno, Italy, June 28-July 3, 2014.
38. Design, Synthesis and Biochemical Evaluation of Novel Electrophilic and Photoaffinity Covalent Probes to Map the CB₁ Receptor Allosteric Site(s). Kulkarni, A. R., Pushkar M. Kulkarni, Anisha

- Korde, Nikolai Zvonok, Maria G. Cascio, Alexandros Makriyannis, Roger Pertwee and **Ganesh A. Thakur**. World Pharma Congress 2014, Boston, USA.
39. Positive allosteric modulation of CB1 with GAT211 suppresses paclitaxel-induced neuropathic pain while by passing unwanted side effects of CB1 receptor activation. Richard A. Slivicki, Liting Deng, Pushkar M. Kulkarni, Maria Cascio, Roger G. Pertwee, **Ganesh A. Thakur** and Andrea G. Hohmann. International Cannabinoid Research Society (ICRS), Braveno, Italy, June 28-July 3, 2014.
** This work received the best presentation award.*
40. Silent and Allosteric Agonists of $\alpha 7$ Acetylcholine Receptors for the Treatment of Inflammation and Neuropathic Pain. R. L. Papke, N. A. Horenstein, C. Stokes, Cheol-Young Maeng, Abhijit R. Kulkarni, and **Ganesh A. Thakur**, Nicotinic Acetylcholine Receptor 2014 Conference, Cambridge (London), UK.
41. Expeditious Microwave-assisted Synthesis of 4BP-TQS, an ago-PAM of $\alpha 7$ nAChRs, its Stereochemical Requirement and the Target Amino Acids Responsible for Activity. Abhijit R. Kulkarni, Nicole A. Horenstein, Clare Stokes, Lu W Corrie, Cheol-Young Maeng, Jeffrey Deschamps, Roger L. Papke, **Ganesh A. Thakur** American Association of Pharmaceutical Scientists' (AAPS) NorthEast Regional Discussion Group (NERDG), Connecticut, USA, 2014
** This work received the best presentation award.*
42. Enantiomer-specific positive allosteric modulation of the type 1 cannabinoid receptor for the treatment of Huntington's disease. Robert B. Laprairie, Adel Zrein, Amina M. Bagher, Pushkar M. Kulkarni, **Ganesh A. Thakur**, Melanie E. Kelly, and Eileen M. Denovan-Wright, International Cannabinoid Research Society (ICRS), Wolfville, Canada, 2015.
** This work received the best oral presentation award.*
43. Actions of the ago-PAM GAT211 and its enantiomer GAT229 on intraocular pressure and retinal ganglion cell loss in the nee mouse model of ocular hypertension. Elizabeth A. Cairns, Alex J. Straiker, Pushkar M. Kulkarni, Ganesh A. Thakur, William H. Badridge, and Melanie E.M. Kelly. International Cannabinoid Research Society (ICRS), Wolfville, Canada, 2015.
44. Design, synthesis and biochemical evaluation of novel electrophilic and photoaffinity covalent probes to map the CB1receptor allosteric site(s). Abhijit R. Kulkarni, Pushkar M. Kulkarni, Anisha Korde, Nicolai Zvonok, Maria Cascio, Alexandros Makriyannis, Roger G. Pertwee and **Ganesh A. Thakur**. International Cannabinoid Research Society (ICRS), Wolfville, Canada, 2015.
** This work received the best oral/poster presentation award.*
45. Fluorine-walk on GAT211, A Positive Allosteric Modulator of the Cannabinoid 1 Receptor: Identification of Critical Sites for Advancing Structure-activity Relationship Studies. Pushkar M. Kulkarni, Sumanta Garai, Robert B. Laprairie, Melanie Kelly, Eileen Denovan-Wright, Lesley A. Stevenson, Roger Pertwee, **Ganesh A. Thakur**, ICRS, 2016.
46. Mapping Cannabinoid Receptor 1 Allosteric Site(S): Critical Molecular Determinant And Signaling Profile Of GAT100 - A Novel, Potent And Irreversibly Binding Probe. Robert B. Laprairie, Abhijit R. Kulkarni, Pushkar M. Kulkarni, Dow P. Hurst, Diane Lynch, Patricia H. Reggio, David R. Janero, Roger G. Pertwee, Lesley A. Stevenson, Melanie E. M. Kelly, Eileen M. Denovan-Wright, and **Ganesh A. Thakur**, ICRS, 2016.
47. Positive Allosteric Modulators of CB1 Receptor Signaling Produce Synergistic Antinociceptive Effects with Inhibitors of Fatty-Acid Amide Hydrolase And Monacylglycerol Lipase. Richard A. Slivicki, Pushkar M. Kulkarni, Ken Mackie, **Ganesh A. Thakur** and Andrea G. Hohmann. ICRS, 2016

48. Highly efficient, one-pot and scalable microwave-accelerated synthesis of urea derivatives via Curtius rearrangement. Abhijit R. Kulkarni, Sumanta Garai, **Ganesh A. Thakur**, *Chemistry and Pharmacology of Drugs of Abuse*, Northeastern University, Boston, 2016.
49. Novel Pharmacotherapy for Treating Cognitive Dysfunction and Chronic Pain in Alzheimer's disease. Abhijit R. Kulkarni, Qi Ye, Deniz Bagdas, Jonghan Kim, Roger L. Papke, Imad Damaj, **Ganesh A. Thakur**, *Chemistry and Pharmacology of Drugs of Abuse*, Northeastern University, Boston, 2016.
50. Mapping Cannabinoid Receptor 1 Allosteric Site(S): Critical Molecular Determinant And Signaling Profile Of GAT100 - A Novel, Potent And Irreversibly Binding Probe. Robert B. Laprairie, Abhijit R. Kulkarni, Pushkar M. Kulkarni, Dow P. Hurst, Diane Lynch, Patricia H. Reggio, David R. Janero, Roger G. Pertwee, Lesley A. Stevenson, Melanie E. M. Kelly, Eileen M. Denovan-Wright, and **Ganesh A. Thakur**, *Chemistry and Pharmacology of Drugs of Abuse*, Northeastern University, Boston, 2016.
51. Positive Allosteric Modulators of CB1 Receptor Signaling Produce Synergistic Antinociceptive Effects With Inhibitors Of Fatty-Acid Amide Hydrolase And Monacylglycerol Lipase. Richard A. Slivicki, Pushkar M. Kulkarni, Ken Mackie, **Ganesh A. Thakur** and Andrea G. Hohmann. *Chemistry and Pharmacology of Drugs of Abuse*, 2016, NEU, Boston.
52. Highly efficient, one-pot and scalable microwave-accelerated synthesis of urea derivatives via Curtius rearrangement. Abhijit R. Kulkarni, Sumanta Garai, **Ganesh A. Thakur** *Research Showcase* 2016, Department of Pharmaceutical Sciences, BCHS, NEU, Boston.
53. Mapping Cannabinoid Receptor 1 Allosteric Site(S): Critical Molecular Determinant and Signaling Profile of GAT100 - A Novel, Potent and Irreversibly Binding Probe. Robert B. Laprairie, Abhijit R. Kulkarni, Pushkar M. Kulkarni, Dow P. Hurst, Diane Lynch, Patricia H. Reggio, David R. Janero, Roger G. Pertwee, Lesley A. Stevenson, Melanie E. M. Kelly, Eileen M. Denovan-Wright, and **Ganesh A. Thakur**. *Research Showcase* 2016, Department of Pharmaceutical Sciences, BCHS, NEU, Boston.
54. Effects of the type 1 cannabinoid receptor positive allosteric modulator GAT211 on absence seizures and the anxiety-like phenotype of genetic absence epilepsy rats from Strasbourg. Mariam Alaverdashvili, Quentin Greba, Michael Anderson, Andrew J. Roebuck, Wendie N. Marks, Sumanta Garai, Terrance P. Snutch, **Ganesh A. Thakur**, John G. Howland, and Robert B. Laprairie. Presented at the International Cannabinoid Research Society Conference (Leiden, July 31).
55. Positive allosteric modulation Of CB1 receptor signaling to lower intraocular pressure. Anna-Maria Szczesniak, Anaëlle Zimmowitch, Laura Daily, Ken Mackie, Alex Straiker, Peter Schaffer, Sumanta Garai, **Ganesh A. Thakur**, and Melanie Kelly. Presented at the International Cannabinoid Research Society Conference, Leiden, July 31, 2018.
56. Positive allosteric modulation of CB1 cannabinoid receptor signaling Enhances the anti-allodynic effects of morphine and attenuates morphine tolerance. Richard A. Slivicki, Sonali S. Mali, Sumanta Garai, **Ganesh A. Thakur**, and Andrea G. Hohmann. Presented at the International Cannabinoid Research Society Conference, Leiden, July 31, 2018.
57. Exploring the structure-activity relationship of type 1 cannabinoid receptor positive allosteric modulators via "fluorine-walk". Robert B Laprairie, Sumanta Garai, Pushkar M Kulkarni, Eileen M Denovan-Wright, and **Ganesh A. Thakur**. Presented at the Canadian Society for Chemistry Conference Edmonton, May 27, 2018.

58. Structure-activity relationship of CB1R positive allosteric modulators via “fluorine walk”. Sumanta Garai, Peter Schaffer, Pushkar M. Kulkarni, Robert B Laprairie, Anna-Maria Szczesniak, Eileen M Denovan-Wright, Alex Straiker, Roger Pertwee, Melanie Kelly, and **Ganesh A. Thakur**. Presented at the CPDA Conference, Boston, August 1-2, 2018.
59. Development of GAT1508, a Novel Subtype Selective Positive Allosteric Modulator (PAM) for GIRK1/2 Channels as a Novel Pharmacotherapy for Post-Traumatic Stress Disorder. Lucas N. Cantwell, Yu Xu, Yuchen Yang, Sumanta Garai, Abhijit R. Kulkarni, Takeharu Kawano, Leigh Plant, Anantha Shekhar, Diomedes Logothetis, **Ganesh A. Thakur**. Presented at the CPDA Conference Boston, August 1-2, 2018.
60. Discovery of highly biased novel positive allosteric modulators of CB1R. Sumanta Garai, Pushkar M. Kulkarni, Peter Schaffer, Robert B Laprairie, Anna-Maria Szczesniak, Alex Straiker, Roger Pertwee, Melanie Kelly and **Ganesh A. Thakur**. Presented at the CPDA Conference, Boston, August 1-2, 2018.
61. Synthesis and Biological Characterization of Novel Ago-PAM of $\alpha 7$ nAChR, B-973 as a Non-addictive Pain Pharmacotherapy. Sumanta Garai, Krishnamohan Raja, Roger Papke, M. Imad Damaj, **Ganesh A. Thakur**. Presented at *Research Showcase*, Department of Pharmaceutical Sciences, NEU, Boston, June 12, 2018.
62. Development of GAT1508 a Novel Subtype Selective Positive Allosteric Modulator (PAM) for GIRK1/2 Channels as a Novel Pharmacotherapy for Post-Traumatic Stress Disorder. Lucas N. Cantwell, Yu Xu, Yuchen Yang, Sumanta Garai, Abhijit R. Kulkarni, Takeharu Kawano, Leigh Plant, Anantha Shekhar, Diomedes Logothetis, **Ganesh A. Thakur**. Presented at *Research Showcase*, Department of Pharmaceutical Sciences, Boston, June 12, 2018.
63. The small molecule GAT1508 activates brain-specific GIRK1/2 heteromers and facilitates extinction of conditioned fear. Yu Xu, Lucas Cantwell, Andrei I. Molosh, Leigh D. Plant, Dimitris Gazgalis, Stephanie D. Fitz, Erik T. Dustrude, Yuchen Yang, Takeharu Kawano, Sumanta Garai, Sami F. Noujaim, Anantha Shekhar, Diomedes E. Logothetis, **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.
64. Mapping the GAT211 Scaffold *via* a Fluorine- and Nitrogen-Walk Approach Sumanta Garai, Pushkar M. Kulkarni, Peter C. Schaffer David R. Janero, **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.
65. Safer and Effective Pharmacotherapy for Glaucoma through CB1R Biased Ago-PAM. Sumanta Garai, Peter C. Schaffer, Anna-Maria Szczesniak, Luciana M. Leo, Ayat Zagzoog, Asher L Brandt, Tallan Black, Jeffrey R. Deschamps, Alex Straiker, Roger G. Pertwee, Mary E. Abood, Melanie E. M. Kelly, Robert B. Laprairie, and **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.
66. Novel Selective and Potent PAMs of $\alpha 4\beta 2$ nAChR as a Pharmacotherapy for Nicotine addiction. Sahil Seth, Sumanta Garai, and **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.
67. A Comprehensive Investigation of the CB1R Positive Allosteric Modulator, GAT211, by Structural Modifications and Computational Simulations Peter Schaffer, Pushkar Kulkarni, and **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.
68. Synthesis and Pharmacological characterization of Novel (a4)2(b2)3 Nicotinic Acetylcholine Receptor Positive Allosteric Modulators. Sahil Seth, Farah Deba, Samantha Cheeks, Harvens Beuzile, Christie

D. Fowler, **Ganesh A. Thakur**, Ayman Hamouda. 123rd Annual Meeting of the American Association of Colleges of Pharmacy. July 23-27, 2022.

69. Synthesis and Pharmacological Characterization of Novel (α 4) β 2) β 3 Nicotinic Acetylcholine Receptor Positive Allosteric Modulators. Sahil Seth, Farah Deba, Samantha Cheeks, Sumanta Garai, Harvens Beauzile, Josue Gaona, M. Imad Damaj, Christie D. Fowler, Ayman K. Hamouda and **Ganesh A. Thakur**. CPDA conference. 2023, Boston, MA.
70. Targeting Allosteric Modulation of CB1 Cannabinoid Receptor Signaling to Suppress Pain and Opioid Reinforcement. Andrea G. Hohmann, Idaira Oliva, Jonah L. Wirt, Maria Gerasi, Edward Stahl, Christine Brust, Lucas N. Cantwell, Laura Bohn, Alexandros Makriyannis, **Ganesh A. Thakur** and Jonathon D. Crystal. CPDA conference. 2023, Boston, MA.
71. Optimizing Positive Allosteric Modulators to Selectively Target the High Sensitivity (α 4) β 2) β 3 Nicotinic Acetylcholine Receptor, poster presentation. Pradip K. Gadekar, Josue Gaona, Sahil Seth, Harvens Beauzile, Wilder Felix, M. Imad Damaj, Christie D. Fowler, **Ganesh A. Thakur**, Ayman Hamouda. (ASPET) Annual Meeting. May 16-19, 2024. Arlington, VA.
72. Optimizing Positive Allosteric Modulators to Selectively Target the High Sensitivity (α 4) β 2) β 3 Nicotinic Acetylcholine Receptor, poster presentation. Pradip K. Gadekar, Josue Gaona, Sahil Seth, Harvens Beauzile, Wilder Felix, M. Imad Damaj, Christie D. Fowler, **Ganesh A. Thakur**, Ayman Hamouda. 3rd ADDC/ASPET Academic Drug Discovery Colloquium. May 20-21, 2024. Arlington, VA.
73. Design, Synthesis, And Biological Evaluation of Novel Positive Allosteric Modulators Targeting Selectively High Sensitivity (α 4) β 2) β 3 nAChRs, for Treatment of Nicotine Addiction. Pradip K. Gadekar, Josue Gaona, Sahil Seth, Harvens Beauzile, Wilder Felix, M. Imad Damaj, Christie D. Fowler, Ayman Hamouda, **Ganesh A. Thakur**. Pharm Sci Research Showcase 2024, Northeastern University, Boston, MA.
74. Design, Synthesis and Biochemical Evaluation of Novel Positive Allosteric Modulators of α 4 β 2 Nicotinic Acetylcholine Receptors. Wilder A. Felix, Josue Gaona, Pradip K. Gadekar, Nataly Sanchez, Ayman K. Hamouda, **Ganesh A. Thakur**. Pharm Sci Research Showcase 2024, Northeastern University, Boston, MA.

III. RESEARCH FUNDING INFORMATION:

Currently active grants:

1. **1R01DA059985-01A1 NIH/NIDA**

Title: Selective Positive Allosteric Modulators of α 4 β 2 Nicotinic Receptors

Role: PI

Date: 08/01/2024- 05/31/2029

Thakur Lab: \$3,432,289

This proposal will develop novel chemical probes to target the nicotinic acetylcholine receptor (nAChR). The α 4 β 2 nAChR presents in two distinct isoforms: the high sensitivity α 4 β 2 β 3 nAChR, and the low sensitivity α 4 β 2 β 2 nAChR. Our recently published findings have led to the hypothesis that drugs selectively targeting the high sensitivity α 4 β 2 β 3 nAChR may provide a novel, previously undefined

understanding of nicotine's actions, and thus, the chemical probes derived from these studies may thereby lead to the development of more efficacious therapeutics to treat nicotine dependence in humans.

2. 1R01NS140966-01 NIH/NINDS

Title: Selective Probes for Alpha9* Nicotinic Acetylcholine Receptors

Role: PI

Date: 03/01/2025- 02/28/2030

Thakur Lab: \$2,983,044

This project targets the development of non-addictive therapies for chronic inflammatory and neuropathic pain by exploring $\alpha 9$ -containing nicotinic acetylcholine receptors ($\alpha 9^*$ -nAChRs) as novel drug targets. Through the design and optimization of selective small-molecule modulators, the research aims to achieve potent anti-inflammatory and analgesic effects without central nervous system side effects. The work spans compound synthesis, receptor specificity screening, pharmacokinetic profiling, and in vivo efficacy testing. By integrating pharmacological, computational, and translational approaches, the study seeks to advance $\alpha 9^*$ -nAChR modulation as a transformative strategy for pain management.

3. 1R01NS137079-01A1 NIH/NINDS

Title: Development of non-opioid, non-addictive analgesics for treating neuropathic pain

Role: PI

Date: 03/18/2025- 01/31/2030

Thakur Lab: \$3,103,165

This project addresses the unmet need for safe and effective treatments for neuropathic pain by developing novel "dualsteric" cannabinoid ligands that act as CB1 receptor allosteric ago-PAMs and CB2 receptor agonists. These compounds are designed to deliver broad-spectrum analgesia without the psychoactive and dependence-related side effects of traditional CB1 agonists. The multidisciplinary team will synthesize and optimize new analogs, assess their pharmacological and pharmacokinetic profiles, and evaluate their efficacy in preclinical models of neuropathic pain. This innovative approach holds promise for a transformative, non-addictive therapy for chronic pain management.

4. Canadian Institutes of Health Research (CIHR)

Title: Development of Novel Type 1 Cannabinoid Receptor Positive Allosteric Modulators for Infantile Spasms

Role: Co-I (PI: Dr. Robert Laprairie)

Date: 05/01/2020- 03/31/2025

Project Total Cost: \$692,325

Direct Cost only (Thakur Lab): \$100,000

This project examines the development of CB1 receptor positive allosteric modulators (PAMs) and their possible use in the treatment of Infantile Spasms, a debilitating form of epilepsy that occurs mainly in the young for which current treatments are largely inadequate. The Aims of the study are to characterize the CB1R allosteric modulator binding site (1) as well as the in vivo effects of novel CB1R PAMs (2), and finally to test these new drugs in two relevant animal models of epilepsy (3).

5. NSF, STTR Phase I; Award Number (FAIN): 2432890

Title: New Paradigm for Combination Drug Optimization and Discovery

Role: Co-I (PI: Dr. Sam Scarpino)

Recipient (Legal Business Name): DUET BIOSYSTEMS, INC

Date: 03/01/2025- 02/28/2026

Project Total Cost: \$ 274,501

The overall goal of our continued research and development is to validate technical and commercial feasibility of the Duet technology 3-part platform based on: 1. A proprietary algorithm, 2. Data acquisition expertise, and 3. An Artificial Intelligence engine. The critical questions to answer in this Phase I are focused on 2. Data Acquisition Expertise. Specifically: i) can MuSyC accurately predict synergy of combinations when trained on disparate data types?; ii) is the scope of necessary MuSyC training data compatible with industry-wide standard assays?; iii) will MuSyC synergy predictions from multi-feature assays (such as Cell Painting) position Duet for future development of powerful AI learning methods trained on MuSyC synergy calculations (a goal for Phase II)?

Completed grants:

1. 2R01GM057481-17 NIH/NIGMS

Title: Targeting the Alpha7 nAChR for Therapeutic Effects

Role: Co-I (PI on subcontract)

Date: 03/01/2020- 02/28/2024

Thakur Lab: \$68,000 (for Yr. 2022)

The proposal aims to develop novel compounds (ago-PAMs and silent agonists) selectively targeting $\alpha 7$ nAChR with desired cytokine profiles and good predicted pharmacokinetic properties and advance them into animal models of neuropathic and inflammatory pain.

2. RO1HL059949-23 NIH/NHLBI

Title: Structural Determinants of PIP2 Regulation

Role: Co-I (PI- Dr. Logothetis)

Date: 07/01/2020- 06/30/2024

Total Requested Cost: \$3,865,654.

Total Cost (Thakur Lab) = \$353,400

The proposal aims to set the stage in coupling the molecular insights of small molecule regulators of activity to specifically reverse the PKC-mediated overstimulation of GIRK channel activity. Our small molecule inhibitors will be tested in transgenic models of PKC-mediated AF with the goal to dial down the aberrant activity enough to correct the AF problem without compromising cardiac health.

3. 1R01 EY024717-01/NIH-NEI

Title: A Novel Pharmacotherapy for Glaucoma

Role: PI

Date: 09/01/2014- 08/31/2021 (NCE)

Total Cost: \$2,207,605

The goal of this proposal is to optimize 2-phenylindole class of CB1 Positive Allosteric Modulators and establish the therapeutic utility of optimized candidates in reducing IOP and neuroprotection of RGCs in animal models.

4. R43MH103936 NIH/NIMH

Title: Novel treatment of posttraumatic stress disorder (PTSD)

Role: PI on the subcontract / Anagin Inc. (primary recipient)

Date: 08/01/2014-07/31/2016

Total Cost = \$160,000

The objective of this project is to develop selective and potent, small molecule inhibitors of nNOS-PSD95 protein-protein interaction for treating post-traumatic stress disorder.

5. RO3 DA027113 NIH/NIDA

Early Career Development Award in Chemistry of Drug Abuse and Addiction

Title: Allosteric Modulators of CB1 Cannabinoid Receptor

Role: PI; Date: 08/01/2009-07/31/2013

Total Cost = \$390,000

The primary goal of this project is to develop high affinity, potent and efficacious negative allosteric modulators of the CB1 receptor, based on structure of the current lead PSNCBAM-1.

6. Undergraduate Research Creative Endeavor Award

Student Name: Mr. Ethan Rawl

My Role: Mentor

Title: Positive Allosteric Modulators of CB1R for Treating Neuropathic Pain

Total Cost: \$3000

Date: November 2018

7. R01CA206028 NIH/NCI

Title: (PQ9) Mitigation of Chemotherapy Induced Peripheral Neuropathy

Role: PI on the subcontract/Dr. David Gewirtz; VCU (Primary recipient)

Date: 04/15/2016-03/31/2017

Total Cost = \$1,733,136

Total Cost (Thakur Lab year 1 only) = \$88,257

The objective of this project is to test utility of $\alpha 7$ nAChR silent agonists and partial agonists to prevent or ameliorate the development of peripheral neuropathy induced by chemotherapy drugs cisplatin and paclitaxel.

8. Undergraduate Research Creative Endeavor Award Northeastern University Provost's Office

Student Name: Ms. Angela Sung

My Role: Mentor

Title: Novel Allosteric Modulators of CB1R Receptor

Total Cost: \$3000

Date: December 2016

9. R01DA026795 NIH/NIDA

Title: Novel Medications for Cannabis Dependence

Role: Co-Investigator; Makriyannis (PI);

Date: 07/15/2009- 05/31/2014

Total Direct Cost: \$397,860/year to CDD.

The goal of this project is to develop novel medications for the clinical management of cannabis dependence and addiction. In this work, we developed compounds with improved 'druggability', i.e., predictable and controllable time course and inactivation through detoxification to inactive metabolic products.

10. Davis Foundation Post-doc Fellowship Program in Eating Disorder Research

Title: Positive Allosteric Modulators of CB1 Cannabinoid Receptor for treatment of Anorexia Nervosa. (Dr. Pushkar Kulkarni, postdoctoral fellow)

Role: Mentor

Date: 07/01/2012- 06/30/2015

Total Cost: \$153,000.

11. Indo-US Singh Obama Post-doctoral Fellowship Program

Title: Development of peripherally acting CB2-selective ligands.

(Dr. Ganesh Chaturbhuj, post-doctoral fellow)

Role: Mentor

Date: 10/01/2013- 09/30/2014

Total Cost = \$30,000

IV. MAJOR COMMITTEE ASSIGNMENTS

A. Service to the Department of Pharmaceutical Sciences, School of Pharmacy and BCHS.

2011- 2013	Member, Faculty Research Development and Mentoring.
2012- current	Scholarship and Award Committee (SOPPS).
2012	John Neumeyer Award Committee (Pharm Sci).
2013-2024	Assessment Committee (SOPPS).
2013-Present	Pharm Sci Research Showcase – coordinator (Pharm Sci)
2017-2018	BCHS Faculty Council (BCHS)
2013-2017	Member, Merit Review Committee (Pharm Sci)
2015-2020	Faculty Development and Recognition Committee (BCHS)
2015-2020	Faculty Development Committee (BCHS)
2018- 2024	Curriculum committee (SOPPS)
2018- current	Executive committee (SOPPS)
2017- current	Dean's Leadership Team (BCHS)
2017-2018	Vice Chair, Department of Pharmaceutical Sciences
2018-2020	Interim Chair, Department of Pharmaceutical Sciences
2020- current	Chair, Department of Pharmaceutical Sciences

B. NIH and International Grant Committees:

2014	NIH Study Section, Drug Discovery for the Nervous System, Ad Hoc reviewer, June 2014
2014	NIH Study Section, Special Emphasis Panel, Molecular Probes, June 2014
2014	NIH Study Section, DDNS, Ad Hoc reviewer, October 2014
2014	NIH Study Section, Special Emphasis Panel, Molecular Probes, Ad Hoc Reviewer, 2014
2016-2017	RRD8 Study Section, Career Development Award Review Committee, US Department of Veteran Affairs, Ad Hoc Reviewer
2016	NIH, Behavioral Neuroscience Fellowship Study Section, ZRG1 F02A-K (20)
2016	NIH Study Section, Small Business: Drug Discovery for Aging, Neuropsychiatric and Neurologic Disorders, ZRG1 ETTN-M (11).
2017	Auckland Medical Research Foundation, Auckland, NZ.
2017	Research Council UK (RCUK)

2019	Member of NIH Study Section, SBIR/STTR Review Panel; ZRG1 BCMB-G (10) B; Drug Discovery & Development
2020-	Member of NIH Study Section, Special Emphasis Panel: Step Up for Substance Use Disorders (SUD)- A Drug Target Initiative for Scientists Engaged in Fundamental Research; U18 Grants.
2022	New Zealand Government's Marsden Funds (July 2022).
2022	NIH Study Section, Drug Discovery for the Nervous System, Ad Hoc reviewer, June 2022
2022	NINDS Special Emphasis Panel, ZNS1 SRB-R (03), Initial Translation Efforts for Non-addictive Analgesic Therapeutics Development (HEAL U19); Feb 2022
2023	NINDS HEAL U19, ZNS1 SRB-R (11); Feb 2023.
2023	Drug Discovery and Molecular Pharmacology B Study Section (DMPB), Feb 2023
2023	UG3/UH3 NINDS/HEAL special emphasis panel ZNS1SRB-V (03); June 2023
2023	NCI/NIH ZCA1 TCRB-J (J2); SEP-8: NCI Clinical and Translational Cancer Research
2024	NINDS Special Emphasis Panel, ZNS1 SRB-R (18), U19; Feb 2024.
2024	SEP-8: NCI Clinical and Translational Cancer Research Review Committee
2024	NINDS Special Emphasis Panel, HEAL Initiative: Non-addictive Analgesic Therapeutics Development to Treat Pain (UG3/UH3)

C. Journal Reviewer (selected list)

- 1) Chemical Biology and Drug Design
- 2) Expert Opinion on Therapeutic Patents
- 3) Bio-organic Medicinal Chemistry
- 4) Chem Bio Chem (Wiley VCH-de)
- 5) Recent Patents on CNS Drug Discovery
- 6) Life Sciences
- 7) Journal of Pharmacology and Experimental Therapeutics (JPET)
- 8) Neuropsychopharmacology, Nature Publishing Group (NGP)
- 9) Bio-organic Medicinal Chemistry Letters
- 10) Drugs of the Future
- 11) Journal of Medicinal Chemistry
- 12) Journal of Organic Chemistry
- 13) ACS Chemical Neuroscience
- 14) Frontiers in Pharmacology, section Translational Pharmacology

D. MEMBERSHIP PROFESSIONAL SOCIETIES

1999- current Association of Carbohydrate Chemists and Technologists

2000- current American Chemical Society

2003- current International Cannabinoid Research Society (ICRS)

2008- current Member of NIDA Networking Project (NNP)

2010- current Member of American Association of Pharmaceutical Scientists (AAPS)

2011- current Member of Rho Chi Honor Society

2015- 2017 Member of Society of Neuroscience

MAJOR TEACHING EXPERIENCE

2006-2010: Assistant Research Professor (CDD; Northeastern University)

2010-2021: Assistant/Associate Professor (Northeastern University)

2021-present: Professor (Northeastern University)

Graduate Courses

2011-2020 : Drug Discovery Journal Club (PHSC6300-003; Fall semester)- Course Coordinator

2011 : Chemistry and Biology of Drugs of Abuse (PHSC6222; Fall semester)

2013- Present : Pharmacokinetics and Drug Metabolism (PMST6252; Spring semester)

2016- 2019 : Principles of Drug Design (PHSC5400; Fall semester);

Undergraduate Courses

2006-2020 : Pharmacology and Medicinal Chemistry I (PHSC4501); Principal instructor for teaching medicinal chemistry

2007-2021 : Pharmacology and Medicinal Chemistry II (PHSC4502); Course coordinator and Principal instructor for teaching medicinal chemistry (Course Coordinator)

2014-Present : Anti-infective Agents (PHSC5360)

RESEARCH MENTORING: (* indicate students for whom my role is mentor as well as advisor)

UNDERGRADUATE MENTORING:

#	Year	Student's name	Degree	Current Position
1	08/2011-12/2011	Shivan Acharya	Pharm.D.	Clinical Pharmacist, CA.
2.	01/2012-04/2012	Monica Taing	Pharm. D	Medical Science Liaison, 4Front
3.	02/2014- 09/2014	Olatokunbo Onabanjo	Pharm. D.	Graduated from NEU
4.	02/2014- 08/2014	Lucia Zhu	Pharm. D.	Graduate from NEU
5.	09/2018- 04/2019	Ethan Rawl	Pharm. D.	Current Student at NEU (P4)
6.	09/2016 – 12/2017	Angela Sung	Pharm. D.	PGY-1 Pharmacy Resident
7.	10/2019- 02/2020	Mark DiFulvio	Pharm.D.	Student at NEU (P1)
8.	09/2021- current	Tavesh Gadkari	B.S. Pharm Sci	Third year student at NEU
9.	08/2022- current	Andrew Wohlbruck	B.S. Pharm Sci	Third year student at NEU
10.	08/2022- current	Aisha Bailey	B.S. Pharm Sci	Third year student at NEU
11.	08/2023- current	James Saskowsky	B.S. Pharm Sci	Second year student at NEU

PH.D./M.S. THESIS MENTORING:

1.	1999-2001	Alok Singh*	M.S. Med. Chem.	Novartis (NIBR), MA.
2.	2003-2006	Jin Zhang*	M.S. Med. Chem.	Harvard Medical School, MA.
3.	01/2007-08/2007	Vince Abeyta ⁺ *	M.S. Med. Chem.	Boehringer Ingelheim, CT.
4.	2007-2011	Heidi Teng*	Ph.D. Med. Chem.	Aldrich, MA.
5.	2010-09/2011	Abhijit Kulkarni	M.S. Med. Chem.	Eli Lilly, Philadelphia
6.	09/2011-04/2012	Khushbu Shah	M.S. Med. Chem.	Scientific Advisor at Kramer Levin
7.	09/2012-09/2014	Prisca Mungalachetty	M.S. Med Chem.	Novartis (NIBR), Boston
8.	09/2011-12/2012	Ameya Ranade	M.S. Med. Chem.	Pursuing Ph.D. in Canada
9.	10/2011-11/2013	Vasantha Duggirla	M.S. Med Chem.	
10.	2007-06/2012	Marsh D'Souza*	Ph.D. Med. Chem.	Post-doc at Scripps
11.	2006-06/2012	Rishi Sharma*	Ph.D. Med. Chem.	Scientist at MicroConstants Inc.
12.	2007-08/2012	Shama Bajaj*	Ph.D. Med. Chem.	MIT, Cambridge, MA.
13.	10/2008-10/2012	Ritesh Tichkule**	Ph.D. Med Chem.	Novartis (NIBR), Boston.
14.	09/2011-08/2016	Abhijit Kulkarni	Ph.D. Med. Chem.	Eli Lilly, Philadelphia
15.	02/2014-08/2015	Siddhi Honavar	M.S. Med. Chem.	GSK, Philadelphia
16.	09/2014-08/2016	Sharvik Shirodkar	M.S. Med Chem.	Kaleido Biosciences, Inc.
17.	09/2014-08/2016	Ninad Dixit	M.S. Med Chem.	Radikal Therapeutics Inc.
18.	09/2016-05/2022	Peter Schaffer	M.S. Med Chem.	Looking for a job in pharma.
19.	09/2017-05/2022	Lucas Cantwell	M.S. Med Chem	Pliant Therapeutics, San Fransico,.
20.	09/2018- 08/2019	Sahil Seth	M.S. Med Chem	Takeda, Cambridge, MA.
21.	09/2018 – 05/2020	Wilder Felix	M.S. Med Chem (Thesis)	
22.	09/2020-currrent	Wilder Felix	Current Ph.D. student	
23.	09/2021- current	Harvens Beauzile	Current Ph.D. student	
24.	09/2023- current	Sahil Seth	Current Ph.D. student	
25.	09/2024- current	Jake Edington	Current Ph.D. student	

 * indicates my role as co-advisor; + indicates my role as mentor

POST-DOCTORAL FELLOW MENTORING:

1.	2005-2008	Dr. Vidyanand Shukla*	---	Millipore Sigma, Natick, MA.
2.	2007-2009	Dr. Shaine Cararas*	---	Researcher, Louisiana
3.	02/2011-08/2015	Dr. Pushkar Kulkarni (Davis Foundation Fellowship)	---	Barnett Institute/Department of Pharm. Sci. NEU
4.	10/2013-09/2014	Dr. Ganesh Chaturbhuj (Indo-US project; Raman Fellowship)	---	Professor, Institute of Chemical Technology (ICT), Mumbai, India.

5.	05/2015-04/2016	Dr. Gopalkrushna Waghule	Zydus Pharma, India
6.	09/2016-08/2017	Dr. Abhijit Kulkarni	Eli Lilly, Philadelphia.
7.	01/2015-12/2022	Dr. Sumanta Garai (Senior Research Scientist)	Scientist II, Carmot Therapeutics, Berkley, CA.
8.	08/2022- 07/2024	Dr. Hina Andleeb	Visiting Assisting Professor, University of West Florida.
9.	02/2022- present	Dr. Pradip Gadekar	Current Research Scientist, NU.

GRADUATE STUDENT THESIS COMMITTEE

1.	2007-2012	Shama Bajaj, (Ph.D.; Medicinal Chemistry)
2.	2007-2012	Ritesh Tichkule, (Ph.D.; Medicinal Chemistry)
3.	2011- 2013	Namita Dodwadkar, (Ph.D.; Pharmaceutics)
4.	2011-2013	Vasanth Duggirala, (M.S.; Medicinal Chemistry)
5.	2011-2013	Ameya Ranade, (M.S.; Medicinal Chemistry)
6.	2012-2014	Madhura Deshpande, (Ph.D.; Pharmaceutics)
7.	2012-2014	Prisca Mungalachetty, (M.S.; Medicinal Chemistry)
8.	2013-2015	Siddhi Honavar, (M.S.; Medicinal Chemistry)
9.	2012-2017	Pranali Deshpande, (Ph.D.; Pharmaceutics)
10.	2011- 2016	Abhijit Kulkarni, (Ph.D.; Medicinal Chemistry)
11.	2014- 2016	Ninad Dixit, (M.S.; Medicinal Chemistry)
12.	2014- 2016	Sharvik Shirodkar (M.S.; Medicinal Chemistry)
13.	2012- 2017	Aditi Jhaveri (M.S.; Pharmaceutics)
14.	2016- 2020	Prisca Mungalachetty (Ph.D.; Bioanalytical Chemistry).
15.	2016-2018	Krishnamohan Raja (M.S.; Medicinal Chemistry)
16.	2017-2019	Sahil Seth (M.S.; Medicinal Chemistry)
17.	2015-2021	Peter Schaffer, (Ph.D.; Medicinal Chemistry)
18.	2016-2021	Lucas Cantwell, (Ph.D.; Medicinal Chemistry)
19.	2018-2020	Wilder Felix, (M.S.; Medicinal Chemistry)
20.	2015-2020	Jiayi Pan, (Ph.D.; Pharmaceutics)

INVITED TALKS:

1. “*Endocannabinoid System as an Emerging Therapeutic Target*” given at Institute of Chemical Technology (ICT, formerly UDCT), Matunga, Mumbai (2011). This lecture was sponsored by Department of Pharmaceutical Sciences and Technology, UGC-Center for Advance Studies, India.

2. *"Cannabinoid Receptors as Therapeutic Targets"* given at Bombay College of Pharmacy (BCP), Mumbai, India (2011).
3. *"Targeting Obesity with Negative Allosteric Modulators of CB1 Cannabinoid Receptor"* in Discovery of Target meeting, (2012).
4. *"Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptor"* given in the department of Pharmaceutical Sciences, St. John University, (2013).
5. *"Allosteric Modulators of CB1 Cannabinoid Receptor"* given in the department of pharmacology and therapeutics, University of Florida, (2013).
6. *"Tuning Endocannabinoid System for Therapeutic Gain"* given at ICT, India, on 28th March 2014.
7. *"Novel Therapeutic Opportunities via Allosteric Modulation of CB1 Cannabinoid Receptor"* given at Indian Institute of Science Education and Research (IISER), Pune, India, (2014).
8. *"Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptor"* given at Indian Institute of Technology (IIT), Bombay, India, (2014).
9. *"Novel Therapeutic Opportunities via Allosteric Modulation of CB1 Cannabinoid Receptor"* given at McLean Hospital, Harvard Medical School, Belmont, MA, (2014).
10. *"Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptors"* given at School of Medicine, Dept. of Neuroscience, University of New Mexico, Albuquerque, NM, (2014).
11. *"Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptors"* given at Dept. of Chemistry and Biochemistry, UMASS Dartmouth, MA, (2014).
12. *"Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptors"* given at the Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI, (2014).
13. *"Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor"* given at the Dept. of Pharmaceutical Sciences, Duquesne University, Pittsburg, PA, (2014).
14. *"Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor"* given at the Dept. of Pharmacology and Molecular Sciences, John Hopkins School of Medicine, Baltimore, MD, (2014).
15. *"Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor"* given at the Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, (2014).
16. *"Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor"* given at 2nd International Congress of Society for Ethnopharmacology, Nagpur, India, (2015).
17. *"Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor"* given at National Chemical Laboratory, NCL, Pune, (2015).
18. *"Therapeutic Potential of CB1 Allosteric Modulators"* given at Nagpur University, India, September 2017.
19. *"Positive Allosteric Modulation of CB1 Cannabinoid Receptor as a Promising Therapeutic Strategy for Treating Pain, Glaucoma and Neurodegenerative Disorders"* given at Temple University, Philadelphia, May 2018.
20. *"Allosteric Modulation of CB1 Cannabinoid Receptor"* given at IISER, Pune, India (2019).
21. *"CB1 Positive Allosteric Modulators for Treating Anxiety Disorders"* Society of Biological Psychiatry, 74th Annual Meeting, May 16-18, 2019, Chicago, IL.

Ganesh A. Thakur; May 18, 2025

22. Invited speaker at: 8th International symposium on Current Trends in Drug Discovery Research: Ageing Associated Metabolic & CNS Disorders, 12 - 14 March, 2022. CSIR-Central Drug Research Institute, Lucknow